MS Patients Have New Option to Improve Walking: Patients treated with extended-release dalfampridine had faster walking speeds than those on placebo.

The Food and Drug Administration's approval of a sustained-release formulation of the potassium channel blocker dalfampridine in January marked the first multiple sclerosis drug that has been specifically indicated for improving walking.